# US 10,441,553 B2 · Fluorinated CBD compounds, compositions and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,441,553 B2
- Document ID: US10441553B2
- Status: Granted
- Kind: B2
- Application number: 15/666,128
- Filed: 2017-08-01
- Published: 2017-11-16
- Granted: 2019-10-15
- Earliest claimed: 2013-01-08
- Assignees: Universidade de Sao Paulo-USP; Universidade Federal Do Rio Grande Do Sul—Ufrgs; Yissum Research Development Company of the Hebrew University of Jesusalem Ltd
- Applicants: Yissum Research Development Company of the Hebrew University of Jerusalem Ltd; Universidade De Sao Paulo—Usp; Universidade Federal Do Rio Grande Do Sul—Ufrgs
- Inventors: Raphael Mechoulam; Antonio Waldo Zuardi; Flavio Pereira Kapczinski; Jaime Eduardo Cecilio Hallak; Francisco Silveira Guimaraes; Jose Alexandre de Souza Crippa; Aviva Breuer
- Web page: https://patentgrep.com/patent/US10441553B2

## CPC

- A61K 31/055: the aromatic ring being substituted by halogen
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 1/08: for nausea, cinetosis or vertigo; Antiemetics
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 7/04: Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 13/12: of the kidneys
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/08: Antiepileptics; Anticonvulsants
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/18: Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A61P 25/22: Anxiolytics
- A61P 25/24: Antidepressants
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 25/30: for treating abuse or dependence
- A61P 25/36: Opioid-abuse
- A61P 27/02: Ophthalmic agents
- A61P 27/12: for cataracts
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 39/06: Free radical scavengers or antioxidants
- C07C 39/373: with all hydroxy groups on non-condensed rings and with unsaturation outside the aromatic rings
- C07C 39/42: containing six-membered aromatic rings and other rings
- C07C 69/16: of dihydroxylic compounds
- C07C 69/63: of saturated acids
- C07C 2601/16: the ring being unsaturated
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS

## Abstract

The present invention relates to fluorine substituted CBD compounds, compositions thereof and uses thereof for the preparation of medicaments.

## Claims

### Claim 1

A method of treating a condition, disease or disorder in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound having the general formula (V):
wherein
R1 is selected from straight or branched C1-C8 alkyl;
R2 is selected from straight or branched C2-C10 alkenyl;
R3 and R4 are OH;
R5 is selected from a straight or branched C5-C12 alkyl;
wherein the condition, disease or disorder is selected from the group consisting of anxiety, depression, schizophrenia, epilepsy and convulsions.

### Claim 2 (depends on 1)

The method of claim 1, wherein the condition, disease or disorder is anxiety.

### Claim 3 (depends on 1)

The method of claim 1, wherein the condition, disease or disorder is depression.

### Claim 4 (depends on 1)

The method of claim 1, wherein the condition, disease or disorder is schizophrenia.

### Claim 5 (depends on 1)

The method of claim 1, wherein the condition, disease or disorder is epilepsy.

### Claim 6 (depends on 1)

The method of claim 1, wherein the condition, disease or disorder is convulsions.

### Claim 7 (depends on 1)

The method of claim 1, wherein the compound is:

### Claim 8 (depends on 7)

The method of claim 7, wherein the condition, disease or disorder is anxiety.

### Claim 9 (depends on 7)

The method of claim 7, wherein the condition, disease or disorder is depression.

### Claim 10 (depends on 7)

The method of claim 7, wherein the condition, disease or disorder is schizophrenia.

### Claim 11 (depends on 7)

The method of claim 7, wherein the condition, disease or disorder is epilepsy.

### Claim 12 (depends on 7)

The method of claim 7, wherein the condition, disease or disorder is convulsions.

### Claim 13

A method of treating inflammation in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound having the general formula (V):
wherein
R1 is selected from straight or branched C1-C8 alkyl;
R2 is selected from straight or branched C2-C10 alkenyl;
R3 and R4 are OH;
R5 is selected from a straight or branched C5-C12 alkyl.

### Claim 14 (depends on 13)

The method of claim 13, wherein the compound is: